Discovering Your Genetic Risk: Cancer Genetic Test for Personalized Insights
351 Clinically Significant Onco Genes
Trusted by over 10000+ oncologists globally
Sequencing depth of up-to 3000x with a total raw output of 10 GB per sample
Genomic testing for Cancer Treatment & Management
Offering world’s most trusted comprehensive genomic profiling test with in-depth insights on patients’ clinically relevant biomarkers and genomic alterations matching with FDA approved targeted therapies and immunotherapies.
Cancer Genomics is a Next Generation Sequencing (NGS) based in vitro diagnostic test that uses targeted high throughput hybridization-based capture technology using DNA isolated from Formalin-Fixed Paraffin Embedded (FFPE) tumor tissue specimens and peripheral whole blood extracted circulating DNA.
It screens for Single Nucleotide Polymorphisms (SNPs), Insertion and Deletions (indels), Copy Number Alterations (CNAs) in 351 genes, select gene rearrangements, as well as genomic signatures including Homologous Recombination Repair (HRR) mutations, Microsatellite Instability (MSI) and Tumor Mutational Burden (TMB).
As a trusted partner of choice in companion diagnostics, GenepoweRx helps to advance Personalized Healthcare in India by delivering diagnostic confidence through a broad range of genomic tests. Our standardized, fully-automated and cloud-supported solutions enable rapid turnaround time, empowering physicians to make the right treatment decisions more quickly.
Next Generation Sequencing using Illumina
The proprietary Indian population specific database of variants
Official partners of MSK’s Precision Oncology Knowledge Base
Cancer Genomics is registered as Class – C medical devices with CDSCO (Reg. No: Uppalu-Hy-der-TE/M/IVD/008407)
Strict quality control measures at different stages of sample processing, data acquisition and analysis adhering to international clinical laboratory practice guidelines
The test is validated in-house and the mean sequencing depth of the Cancer Genomics is up-to 3000x with a total raw data output of 10 GB per sample
High throughput NGS data analysis, curation, and interpretation of the mutations are performed by well-experienced clinical scientists/genome analysts and cancer genome experts
Cancer Gene Test Report
In addition to FDA approved therapies, Cancer Genomics also offers clinically actionable, personalized Pharmacogenomics (PGx) & Nutrigenomics (NGx) report.
PGx report helps in prescribing the right medication by studying the CPIC & PharmGkb approved Biomarkers. NGx profile helps in structuring a personalized nutrition regimen based on an individual’s genetic profile and metabolism.
Simplified oncologist friendly report
Clinically actionable prescriptive insights to oncologists
Information on available active clinical trials
Nutrigenomics (NGx)
Druggable alterations and their associated FDA approved therapies
personalized Pharmacogenomics (PGx)
Recommended targeted therapies & possible mechanisms of resistance
OncoKB Therapeutic Levels of Evidence
FDA-recognized biomarker predictive of response to an FDA-approved drug in this indication
Standard care biomarker recommended by the NCCN or other professional guidelines predictive of response to an FDA-approved drug in this indication
Compelling clinical evidence supports the biomarker as being predictive of response to a drug in this indication
Standard care or investigational biomarker predictive of response to a FDA-approved or investigational drug in another indication
Compelling biological evidence supports the biomarker as being predictive of response to a drug
Standard care biomarker predictive of resistance to an FDA-approved drug in this indication
Compelling clinical evidence supports the biomarker as being predictive of resistance to a drug
Non-Small Cell Lung Cancer
EGFR exon 19 deletions & EGFR exon 21 , L858R alterations
Gilotrif® (afatinib), Iressa® (gefitinib), Tagrisso® (osimertinib), or Tarceva®
EGFR exon 20 T790M alterations
Tagrisso® (osimertinib)
ALK rearrangements
Alecensa® (alectinib), Alunbrig® (brigatinib) Xalkori® (crizotinib), or Zykadia® (ceritinib)
BRAF V600E
Tafinlar® (dabrafenib) in combination with Mekinist® (trametinib)
MET single nucleotide variants (SNVs) and indels that lead to MET exon 14 skipping
TabrectaTM (capmatinib)
Breast Cancer
ERBB2 (HER2) amplification
Herceptin® (trastuzumab), Kadcyla® (ado trastuzumab-emtansine), or Perjeta® (pertuzumab)
PIK3CA C420R, E542K, E545A, E545D [1635G>T only], E545G, E545K, Q546E, Q546R, H1047L, H1047R, and H1047Y alterations
Piqray® (alpelisib)
Colorectal Cancer
KRAS wild-type (absence of mutations in codons 12 and 13)
Erbitux® (cetuximab)
KRAS wild-type (absence of mutations in exons 2, 3, and 4) and NRAS wild type (absence of mutations in exons 2, 3, and 4)
Vectibix® (panitumumab)
Ovarian Cancer
BRCA1/2 alterations
Lynparza® (olaparib) or Rubraca® (rucaparib)
Prostate Cancer
Homologous Recombination Repair (HRR) gene (BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D and RAD54L) alterations
Lynparza® (olaparib)
All Solid Tumors
TMB ≥ 10 mutations per megabase
Keytruda® (pembrolizumab)
NTRK1/2/3 fusions
Vitrakvi® (larotrectinib)
Cancer Genomics is intended as a companion diagnostic to identify patients who may benefit from treatment with the targeted therapies in accordance with the approved therapeutic product labeling.
Treating oncologists can also decide ideal candidates who can benefit from this test by means of immunotherapies, targeted therapies and personalized pharmacogenomic.| Tests |
|---|
| Next-Generation Sequencing |
| MSK(Memorial Sloan Kettering) Cancer Center Knowledge Base |
| Number of Genes |
| Depth |
| Homologous Recombination Repair (HRR) |
| Programmed Death Ligand - 1 |
| Micro Satellite Instability (MSI) |
| Tumor Mutational Burden (TMB) |
| Pharmacogenomics |
| Nutrigenomics |
| Comprehensive | Mini | Condition Specific |
|---|---|---|
| 351 | 71 | 16-24 |
| 3000X | 1000X | 1000X |
Official Analytics partner
The world’s oldest and largest private cancer center, and GenePower(by K&H), partnered into collaboration that will utilize MSK’s clinical and research insights into gene mutations associated with solid tumors along with K&H proprietary database to provide accurate recommendations for Indian population .
Highlights
A directional test for tumor profiling enabling oncologists to predict response/ resistance to targeted and immuno-therapies for cancer patients over the traditional molecular testing.
Over 5600 genomic alterations covered-
We are the only company in Genomics space
lead by physicians in India.
Simplified reports
Open Discussion channel
between Oncologist, Pathologist and genomic specialist physician will lead to best treatment choices for the patient.
GenePower OncoRx uses targeted genomic sequencing and analysis to provide the physician with information on-
- Druggable mutations in your patient for which targeted
therapies are available. - Clinical trial match connector
- Microsatellite Instabilty status (MSI)
- Tumor Mutational Burden status (TMB)
- Sample required- FFPE tissue sample
- TAT(Turn Around Time)- 3- 4 weeks
FAQs
Helping us to deliver precise reports
